第二十屆中國北京國際科技(jì)産業博覽會(huì)參展

科技(jì)部、國家(jiā)知識産權局、中國貿促會(huì)和(hé)北京市政府共同主辦的第二十屆中國北京國際科技(jì)産業博覽會(huì)(以下簡稱科博會(huì))于2017年6月8-10日在中國國際展覽中心開(kāi)展。

2017

06-12

董事長劉青博士參加ClemsonInternationalBiomaterialsSymposium-China會(huì)議

劉青博士應GuigenZhang教授邀請(qǐng)參加了4月10日在美國Clemson大(dà)學舉辦的InternationalBiomaterialsSymposium-China， 并做(zuò)了題為(wèi) “Development of Bioresorbable Tissue Scaffolds Using A New Precision Multi-axial 3D Printing Technology” 的報告

2017

04-14

公司贊助Chinese Association for Biomaterials（CAB,華人(rén)生(shēng)物材料協會(huì)）活動

公司特贊助ChineseAssociationforBiomaterials(CAB,華人(rén)生(shēng)物材料協會(huì))活動

2017

04-14

阿邁特AMSorb全降解冠脈藥物洗脫支架臨床試驗項目啓動會(huì)在西安順利召開(kāi)

阿邁特AMSorbTM全降解冠脈藥物洗脫支架臨床試驗項目啓動會(huì)在西安順利召開(kāi)

2016

09-09

阿邁特3D打印可(kě)降解冠脈血管支架亮相歐洲心髒大(dà)會(huì)

2016年8月30日在意大(dà)利羅馬召開(kāi)的歐洲心髒大(dà)會(huì)上(shàng)，來(lái)自北京大(dà)學第一醫(yī)院霍勇教授團隊的鄭博教授報告了阿邁特自主創新的3D打印可(kě)降解冠脈血管支架臨床前的研究結果。引起與會(huì)者們的極大(dà)興趣。

2016

08-31

Bioresorbable Vascular Scaffold Thrombosis in a Consecutive Cohort of 550 Patients

To determine the rate of bioreasorbable vascular scaffold (BVS) thrombosis in a large, real-world population. BACKGROUND: There is some concern about device thrombosis after percutaneous coronary intervention (PCI) using BVS. No data have been published for PCI using both BVS and metal stents.

2016

08-12

1-year outcomes with the Absorb bioresorbable scaff old in patients with coronary artery disease: a patient-level, pooled meta-analysis

Background Compared with metallic drug-eluting stents, bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention. Whether or not these devices are as safe and effective as drug-eluting stents within the first year after implantation is unknown.

2016

08-12

First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China

To the Editor: A 35-year-old man who smoked for 15 years suffered from chest pain 12 days ago before admission. He was diagnosed as myocardial infarction. Thrombolytic therapy was given consequently. The electrocardiogram showed sub-acute inferior wall myocardial infarction. Echocardiogram showed attenuated constriction of the inferior wall with an ejection fraction of 59%. On September 5, 2013, he was treated with a XINSORB scaffold in right coronary artery (RCA).

2016

08-12

Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents:single-center experience

To assess the midterm efficacy of a biodegradable poly-l-lactic acid (PLLA) stent in the treatment of superficial femoral artery (SFA) occlusive disease.

2016

08-12

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease

In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the metallic stent frame in the coronary-vessel wall. Bioresorbable vascularscaffolds have been developed to attempt to improve long-term outcomes.

2016

08-12

< 1...11121314 > 前往 頁

公司信息

北京飛渡醫療器械有限公司

Beijing Advanced Medical Technologies,Ltd.Inc.

 

聯系我們

地址：北京市大(dà)興區(qū)永旺西路26号院中關村醫(yī)療器(qì)械園11号樓

電(diàn)話(huà)：010-6297-7955             郵箱：amt@ametcorp.com

圖片名稱

微信聯系

@Copyright 2022 北京飛渡醫療器械有限公司 All rights reserved   版權所有(yǒu)

京ICP備11028039号    網站(zhàn)建設：中企動力  南京